Merck has launched its Herceptin biosimilar Ontruzant (rastuzumab-dttb) in the U.S., priced 15 percent lower than Roche’s blockbuster cancer drug.

Merck is launching the product at a wholesale cost of $1,325 for the 150 mg single-dose vial and $3,709 for the 420 mg multiple-dose vial.

The FDA approved Ontruzant in January 2019, based on data demonstrating that it is highly similar to its reference product.